HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory risk assessment bill drops petition provision; bill passes House.

This article was originally published in The Rose Sheet

Executive Summary

REGULATORY RISK ASSESSMENT BILL DROPS PETITION PROVISION that would have given private parties the right to petition agencies to review existing regulations in light of the cost-benefit analysis requirements of the bill. The petition provision, which was included in some earlier incarnations of the bill, was dropped from the floor version of "The Risk Assessment and Cost-Benefit Act" (HR 1022). An amendment by Rep. Joe Barton (R-TX) to reintroduce the provision was defeated Feb. 28.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel